Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26658234 | 0.88 | CYP2C9 (0.33) | ALDH1A1PKMMEN1KMT2AKDM4E | |
| SCHEMBL7267052 | 0.77 | ALDH1A1 (0.37) | ALDH1A1PKMMEN1KMT2AKDM4E | |
| SCHEMBL8912352 | 0.73 | CYP4F2 (0.42) | ALDH1A1PKMMEN1KMT2AKDM4E | |
| SCHEMBL788715 | 0.72 | ALDH1A1 (0.46) | ALDH1A1PKMMEN1KMT2AKDM4E | |
| SCHEMBL8919708 | 0.70 | ALDH1A1 (0.43) | ALDH1A1PKMMEN1KMT2AKDM4E | |
| SCHEMBL6507050 | 0.70 | CYP4F2 (0.48) | ALDH1A1PKMMEN1KMT2AKDM4E | |
| SCHEMBL195662 | 0.70 | CYP4F2 (0.56) | ALDH1A1PKMMEN1KMT2AKDM4E | |
| SCHEMBL5469810 | 0.70 | CYP4F2 (0.44) | ALDH1A1PKMMEN1KMT2AKDM4E | |
| SCHEMBL5936809 | 0.70 | ALDH1A1 (0.43) | ALDH1A1PKMMEN1KMT2AKDM4E | |
| SCHEMBL27540559 | 0.70 | CYP4F2 (0.40) | ALDH1A1PKMMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365608-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | JANSSEN BIOPHARMA, LLC | 2023-11-16 | — | — | US | disclosed |
| US-20230365608-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | JANSSEN BIOPHARMA, LLC | 2023-11-16 | — | — | US | disclosed |
| US-20230365608-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | JANSSEN BIOPHARMA, LLC | 2023-11-16 | — | — | US | disclosed |
| EP-3917922-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | Janssen BioPharma, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020157694-A9 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | Janssen Biopharma, Inc. (US) | 2021-11-11 | — | — | WO | disclosed |
| CN-113382994-A | Antiviral nucleosides and derivatives thereof | 詹森生物制药有限公司 | 2021-09-10 | — | — | CN | disclosed |
| WO-2020157694-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | Janssen Biopharma, Inc. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020157694-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | Janssen Biopharma, Inc. (US) | 2020-08-06 | — | — | WO | disclosed |
| EP-1871770-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | Kalypsys, Inc. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006116355-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | KALYPSYS, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | ALDH1A1 4346/4885PKM 1524/4885MEN1 3740/4885 |
| US-20230365608-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | PNP, NUDT1, ADAR | ALDH1A1 3258/4885PKM 2152/4885MEN1 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.